Elanco’s Post

Trooper was first introduced to Zenrelia™ (ilunocitinib tablets) during the clinical trial. But when the trial ended, this four-year-old Yorkshire Terrier saw the itch return. Once Zenrelia became widely available, his owner, Robin, made it a priority to get her beloved Trooper back on Zenrelia. “Allergies are something he’s going to have to suffer with his whole life,” said Trooper’s pet parent, Robin. “Having a solution for his allergies is such a relief. It makes my heart happy that I will be able to afford it and give him the relief he deserves.” Learn more about how dogs can reach for Zen at Zenrelia.com. IMPORTANT SAFETY INFORMATION See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit https://lnkd.in/gsYNzUhM. WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.